<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04639388</url>
  </required_header>
  <id_info>
    <org_study_id>2020-A01370-39</org_study_id>
    <nct_id>NCT04639388</nct_id>
  </id_info>
  <brief_title>Understanding of Psychotic Disorders in Children With 22q11.2DS</brief_title>
  <acronym>PremiCeS22</acronym>
  <official_title>Characterize the Behavioral Prodromes of Psychotic Disorders in Children With 22q11.2DS Aged From 4 to 13 Years Old</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hôpital le Vinatier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hôpital le Vinatier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study PremiCeS22 will investigate the prodromal signals at the onset of psychotic&#xD;
      disorders of children with 22q11.2 deletion syndrome&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      22q11.2DS is one of the most common microdeletion syndromes (1 / 2000-1 / 4000 births) and&#xD;
      one of the most robust genetic risk factors for schizophrenia (1 to 2% of cases).&#xD;
      Reciprocally, approximately 30% of patients with 22q11.2DS will develop psychotic symptoms in&#xD;
      adolescence or early adulthood. It is now well established that children and adults with&#xD;
      22q11.2DS have lower social skills than developing youth. These social dysfunctions could be&#xD;
      partly underpinned by alterations in social cognitive processes, and could also be linked to&#xD;
      the emergence of psychotic signs or even schizophrenia. However, to our knowledge, no study&#xD;
      has investigated the existence of behavioral prodromal signs during the onset of psychotic&#xD;
      signs in children with 22q11.2DS. In addition, the origin of social cognitive processes&#xD;
      remains to this day little explored.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 13, 2020</start_date>
  <completion_date type="Anticipated">January 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Monocentric study with two parallel groups</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Screen for child Anxiety Related Emotional Disorders (SCARED)</measure>
    <time_frame>Day 1</time_frame>
    <description>Scale assessing behavioral prodromes or warning signs of hallucinations in psychotic disorders A psychometric study is then carried out on this questionnaire in order to validate it with parents of children carrying 22q11.2DS.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>facial expression recognition task</measure>
    <time_frame>Day 1</time_frame>
    <description>Proportion of correct responses in experimental tasks evaluating gaze direction and facial expression recognition</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sustained hearing attention test (Tea-Ch battery)</measure>
    <time_frame>Day 1</time_frame>
    <description>Proportion of impaired scaled score at the Sky Search subtest from the Test of Everyday Attention for Children (TEA-Ch)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rey's Tangled Lines Test</measure>
    <time_frame>Day 1</time_frame>
    <description>Proportion of impaired scaled score to study the degree of cognitive development in children</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NEPSY II battery</measure>
    <time_frame>Day 1</time_frame>
    <description>Proportion of impaired scaled score at auditory attention of NEPSY II battery The NEPSY-II is a comprehensive neuropsychological battery for children ages 3-12. The test provides measures of sensor-motor, language, visuospatial processing, memory and learning, attention/executive functions, and social cognition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean reaction time</measure>
    <time_frame>Day 1</time_frame>
    <description>Mean reaction time in neuropsychological testing and experimental tasks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>22q11.2 Deletion Syndrome</condition>
  <arm_group>
    <arm_group_label>22q11.2DS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children aged from 4 to 13 years old with 22q11.2 deletion syndrome</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group (Non22q11.2DS)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Children aged from 4 to 13 years old without developmental disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>neuropsychological testing, questionnaires and experimental tasks</intervention_name>
    <description>Neuropsychological testing (the Sky Search subtest from the Test of Everyday Attention for Children (TEA-Ch); the Overlapping lines task of Rey; auditory attention of NEPSY II battery); questionnaires completed by the children's legal representatives to assess behavior; experimental tasks evaluating gaze direction and facial expression recognition</description>
    <arm_group_label>22q11.2DS</arm_group_label>
    <arm_group_label>Control Group (Non22q11.2DS)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of 22q11.2 deletion syndrome or no developmental disease&#xD;
&#xD;
          -  Aged from 4 to 13 years old&#xD;
&#xD;
          -  French language&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of intellectual deficiency according to DSM 5 criteria&#xD;
&#xD;
          -  Drug prescribed for somatic condition that could influence cerebral functioning&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>13 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie-Noëlle BABINET</last_name>
    <role>Principal Investigator</role>
    <affiliation>CH LE VINATIER</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Caroline DEMILY, MD PH</last_name>
    <phone>0450915163</phone>
    <phone_ext>+33</phone_ext>
    <email>caroline.demily@ch-le-vinatier.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Véronique VIAL</last_name>
    <phone>0437915531</phone>
    <phone_ext>+33</phone_ext>
    <email>veronique.vial@ch-le-vinatier.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hopital Vinatier</name>
      <address>
        <city>Lyon</city>
        <state>Rhone Alpes</state>
        <zip>69678</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DEMILY MD CAROLINE, PH</last_name>
      <phone>0033437915163</phone>
      <email>caroline.demily@ch-le-vinatier.fr</email>
    </contact>
    <contact_backup>
      <last_name>VIAL VERONIQUE</last_name>
      <phone>0033437915531</phone>
      <email>veronique.vial@ch-le-vinatier.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 1, 2020</study_first_submitted>
  <study_first_submitted_qc>November 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2020</study_first_posted>
  <last_update_submitted>November 17, 2020</last_update_submitted>
  <last_update_submitted_qc>November 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>DiGeorge Syndrome</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

